Publications by authors named "M E Tushuizen"
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely associated with many aspects of disturbed metabolic health. MASLD encompasses a wide spectrum of liver diseases, ranging from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), up to fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Limited noninvasive diagnostic tools are currently available to distinguish the various stages of MASLD and as such liver biopsy remains the gold standard for MASLD diagnostics.
View Article and Find Full Text PDFBackground & Aims: Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) can co-exist in AIH-PBC, requiring combined treatment with immunosuppression and ursodeoxycholic acid (UDCA). The Paris criteria are commonly used to identify these patients; however, the optimal diagnostic criteria are unknown. We aimed to evaluate the use and clinical relevance of both Paris and Zhang criteria.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on creating a blood test to identify fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) using a gene expression signature found in a mouse model.
- Researchers developed a biomarker panel made up of three proteins: IGFBP7, SSc5D, and Sema4D, which effectively predicts different levels of liver fibrosis.
- The new blood-based test shows better accuracy in detecting fibrosis stages compared to existing methods like Fib-4, APRI, and FibroScan, making it a promising tool for diagnosing MASLD-related liver issues.
Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for use in reflex testing algorithms for metabolic dysfunction-associated steatotic liver disease (MASLD).
Clin Chem Lab Med
October 2024